Side-by-side · Research reference

MatrixylvsPancragen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED9/39 cited

BAnimal-StrongHUMAN-REVIEWED23/39 cited

Matrixyl

Cosmeceutical Pentapeptide · Topical Anti-Aging

TopicalRoute

5-AALength (KTTKS)Gomes 2022

Collagen I/IIIPrimary targetPaccola 2025

Topical · Dermal · Twice Daily

Pancragen

Bioregulatory Tetrapeptide · Khavinson School

50 μgPrimate doseGoncharova 2014

10 daysTreatment cycleGoncharova 2015

3+ weeksEffect persistenceGoncharova 2014

IM · 10-day cycleGoncharova 2014

01Mechanism of Action

Parameter

Matrixyl

Pancragen

Primary target

Dermal fibroblastsPaccola 2025

Pancreatic acinar and islet cell differentiation pathwaysKhavinson 2013

Pathway

Fibroblast stimulation → Collagen I/III/IV synthesis → Glycosaminoglycan deposition → ECM remodeling

Transcription factor activation → Pdx1/Pax6/Pax4/Ptf1a/Foxa2/NKx2.2 upregulation → Cell differentiationKhavinson 2013

Downstream effect

Enhanced extracellular matrix synthesis, improved dermal density, collagen remodelingPaccola 2025

Enhanced pancreatic beta-cell function, normalized insulin/C-peptide dynamics, improved glucose clearanceGoncharova 2014

Feedback intact?

—

Yes — preserves physiological glucose-insulin response

Origin

Synthetic pentapeptide KTTKS derived from pro-collagen I fragment, N-palmitoylated for lipophilicityGomes 2022

Synthetic tetrapeptide derived from pancreatic tissue extracts (Khavinson bioregulator methodology)

Antibody development

—

02Dosage Protocols

Parameter

Matrixyl

Pancragen

Formulation concentration

0.5–5% in topical vehicle

Common cosmeceutical range; higher concentrations in clinical formulations.

—

Application frequency

Twice daily (AM/PM)

Standard cosmeceutical protocol.

—

Duration

8–12 weeks minimum for visible effect

Collagen synthesis requires sustained application.

—

In vitro evidence

Fibroblast viability + ECM gene upregulationPaccola 2025

—

Vehicle

Serum, cream, or emulsion base

Lipophilic carriers enhance penetration.

—

Primate dose (rhesus macaque)

—

50 μg / animal / dayGoncharova 2014

20–25-year-old females, 10-day IM protocol.

Effective concentration (in vitro)

—

0.05 ng/mLZakutskiĭ 2006

Organotypic tissue culture, both young and aged rat explants.

Route

—

IntramuscularGoncharova 2015

Frequency

—

Once daily for 10 daysGoncharova 2014

Treatment cycle

—

10-day course, effects persist 3+ weeks post-withdrawalGoncharova 2014

Evidence basis

—

Non-human primate RCT, in vitro cell cultureGoncharova 2015 Khavinson 2013

Diabetes model

—

STZ-induced diabetes (rat)

Evaluated via metabolic markers characterizing apoptosis.

04Side Effects & Safety

Parameter

Matrixyl

Pancragen

Irritation

Mild erythema, pruritus in sensitive skin (rare)

—

Allergic reaction

Contact dermatitis (uncommon)

—

Systemic absorption

Negligible — topical application only

—

Reported adverse events

—

None documented in primate studies

Tolerability

—

Well-tolerated in aged rhesus monkeys (n=9)Goncharova 2015

Human safety data

—

No published human trials; clinical use limited to Russian gerontology protocols

Absolute Contraindications

Matrixyl

·Known hypersensitivity to palmitoyl peptides

Pancragen

—

Relative Contraindications

Matrixyl

·Active dermatitis or open wounds at application site

Pancragen

·Active pancreatic malignancy (proliferation marker upregulation)

05Administration Protocol

Parameter

Matrixyl

Pancragen

1. Cleanse

Wash face with gentle cleanser. Pat dry.

Lyophilised tetrapeptide reconstituted in sterile saline or water per manufacturer protocol. Concentration not specified in literature.

2. Application

Apply 2–3 drops to fingertips. Massage gently into target areas (face, neck, décolletage). Allow 1–2 minutes for absorption.

Intramuscular injection. Primate studies used daily IM dosing for 10 consecutive days.Goncharova 2015

3. Timing

Twice daily — morning and evening. Apply before heavier creams or sunscreen.

No specific timing constraints documented. Administered once daily in primate protocols.

4. Storage

Store at room temperature, away from direct sunlight. Stable in formulation for 12–24 months.

10-day treatment course. Restorative effects on pancreatic function persist for at least 3 weeks post-discontinuation.Goncharova 2014

06Stack Synergy

Matrixyl

+ GHK-Cu

Multi-pathway

View GHK-Cu →

Matrixyl (Pal-KTTKS) stimulates fibroblast collagen synthesis via pro-collagen I mimicry, while GHK-Cu acts as a copper-binding tripeptide that enhances ECM remodeling through metalloproteinase modulation and wound healing pathways. Combined, they address collagen synthesis (Matrixyl) and matrix remodeling/repair (GHK-Cu) through distinct mechanisms, producing complementary effects on dermal architecture.

Matrixyl: 0.5–5% topical serum · AM/PM
GHK-Cu: 1–2% topical serum · same application
Frequency: Twice daily
Primary benefit: Enhanced collagen synthesis + ECM remodeling, improved skin density and elasticity

Pancragen

— no documented stacks